Santhera Pharmaceuticals has reported a 97% increase in total revenue for 2025, driven by the strong market acceptance of AGAMREE® (Vamorolon), a novel dissociative steroid for treating Duchenne Muscular Dystrophy (DMD). CEO Dario Eklund highlighted the company’s strategic partnerships, including collaborations with Nxera in the Asia-Pacific region, Catalyst Pharmaceuticals in the US, and Sperogenix in China, which have significantly expanded patient access and contributed to nearly doubling sales. Long-term clinical data, demonstrating an improved safety profile comparable to standard corticosteroids, further solidifies AGAMREE’s position as a viable long-term treatment option.

The significance of these findings lies in the rapid market penetration of AGAMREE in key European markets, particularly Germany and Austria, where it has captured over 40% and 50% market share, respectively, among corticosteroid-treated DMD patients. The company has also made substantial progress in pricing and reimbursement discussions across Europe, with agreements in Spain and Italy expected to enhance patient access. Catalyst Pharmaceuticals reported $117 million in AGAMREE sales for 2025, triggering a $12.5 million milestone payment to Santhera, underscoring the growing commercial momentum.

The concrete implication of Santhera’s achievements is a potential shift in the treatment paradigm for DMD. The successful integration of AGAMREE into treatment regimens could influence future drug development timelines, encouraging a focus on innovative therapies that offer improved safety and efficacy profiles. As Santhera approaches cash flow break-even in 2026, the momentum from AGAMREE’s commercial success may catalyze further investment and research into similar therapeutic avenues, ultimately enhancing patient outcomes in rare neuromuscular diseases.

Source: globenewswire.com